Clinical Trials Market - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 -(By Phase Coverage, Study Design Coverage, Indication Coverage, Service Type Coverage, Geographic Coverage and Leading Companies)

Report
276 Pages
November 2023
Region: Global
Fairfield Market Research
ID: 5901082

Clinical trials market size to reach approximately US$79.9 Bn in 2030, up from US$52.5 Bn registered in 2022

The global clinical trials market is on an impressive growth trajectory, with forecasts indicating a significant rise from its 2022 valuation of US$52.5 billion to an estimated US$79.9 billion by 2030. This remarkable expansion is expected to witness a strong CAGR of 6.2% during the period from 2023 to 2030.

Key Market Drivers:

Rising Prevalence of Chronic Diseases: The increasing incidence of chronic illnesses is a pivotal driver for the clinical trials market. The need for the development of novel drugs and therapies to enhance the quality of life for patients with chronic conditions propels market growth.

Increased R&D Investment: Major players in the market are significantly boosting their Research and Development (R&D) expenditures, exerting a substantial influence on the industry's expansion. Pharmaceutical, biotechnology, and medical device companies are intensifying their focus on pioneering medicines and technologies, fostering the demand for clinical trials.

Key Market Segments:

Dominance of Phase III Trials: In 2022, the Phase III trials category claimed the largest market share (53.5%). Its widespread implementation, despite high costs, is a major factor contributing to its market dominance. The Phase II trials segment is poised for rapid growth, particularly for COVID-19 treatments.

Interventional Studies at the Helm: Interventional studies took center stage in 2022, being one of the most commonly employed approaches in clinical studies. With innovations in clinical trial methodologies, the expanded access trials segment is anticipated to grow substantially.

Oncology Leads the Way: Oncology emerged as the leading segment in 2022, driven by ongoing research into cancer treatments and the demand for precision medicine. The cardiovascular category is projected to experience the fastest growth due to substantial investments in R&D for cost-effective drugs.

Clinical Trial Data Management Services in High Demand: Clinical trial data management services led market growth in 2022. With an increasing number of clinical trials, technological advancements in monitoring, and stringent data management and security regulations, this category thrives. Laboratory services are set to be the fastest-growing segment during the forecast period.

Regional Outlook:

North America Takes the Lead: North America is expected to hold the largest share of the global clinical trials market. Factors such as substantial R&D spending, well-established players, stringent regulatory frameworks, increasing disease prevalence, and significant contributions from the United States underpin the region's market leadership.

Asia Pacific Emerges as the Fastest-Growing Market: The Asia Pacific region is poised for rapid growth during the forecast period. The region's easily accessible and substantial patient pool simplifies participant recruitment for clinical trials. Government and private organizations' funding for affordable drug delivery, along with the rising prevalence of diseases like obesity, cancer, and cardiovascular conditions, drive market expansion.

Competitive Landscape

The global clinical trials market features fewer large competitors and has witnessed consolidation. Leading companies are expanding their product lines, enhancing distribution networks, and investing in marketing campaigns and social media promotion to further strengthen their global presence.

Leaders in Global clinical trials Space:

Eli Lilly and Company
Syneos Health
Pharmaceutical Product Development (PPD)
Novo Nordisk A/S
Icon plc.
Charles River Laboratories
Parexel International Corporation
WuXi Apptec
Medpace Holdings, Inc.
KCR Pharmaceuticals Pvt. Ltd.
Pharmaceutical Solutions Industry Ltd. (PSI).
Pfizer
Thermo Fisher Scientific Inc.
Sanofi SA

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Clinical Trials Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. Covid-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Clinical Trials Market Outlook, 2018 - 2030

3.1. Global Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Phase I
3.1.1.2. Phase II
3.1.1.3. Phase III
3.1.1.4. Phase IV
3.2. Global Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Interventional
3.2.1.2. Observational
3.2.1.3. Expanded Access
3.3. Global Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. Autoimmune/Inflammation
3.3.1.1.1. Rheumatoid arthritis
3.3.1.1.2. Multiple Sclerosis
3.3.1.1.3. Osteoarthritis
3.3.1.1.4. Irritable Bowel Syndrome (IBS)
3.3.1.1.5. Others
3.3.1.2. Pain Management
3.3.1.2.1. Chronic Pain
3.3.1.2.2. Acute Pain
3.3.1.3. Oncology
3.3.1.3.1. Blood Cancer
3.3.1.3.2. Solid Tumors
3.3.1.3.3. Other
3.3.1.4. CNS Condition
3.3.1.4.1. Epilepsy
3.3.1.4.2. Parkinson's Disease (PD)
3.3.1.4.3. Huntington's Disease
3.3.1.4.4. Stroke
3.3.1.4.5. Traumatic Brain Injury (TBI)
3.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
3.3.1.4.7. Muscle Regeneration
3.3.1.4.8. Others
3.3.1.5. Diabetes
3.3.1.6. Obesity
3.3.1.7. Cardiovascular
3.3.1.8. Others
3.4. Global Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
3.4.1. Key Highlights
3.4.1.1. Protocol Designing
3.4.1.2. Site Identification
3.4.1.3. Patient Recruitment
3.4.1.4. Laboratory Services
3.4.1.5. Bioanalytical Testing Services
3.4.1.6. Clinical Trial Data Management Services
3.4.1.7. Others
3.5. Global Clinical Trials Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa

4. North America Clinical Trials Market Outlook, 2018 - 2030

4.1. North America Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Phase I
4.1.1.2. Phase II
4.1.1.3. Phase III
4.1.1.4. Phase IV
4.2. North America Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Interventional
4.2.1.2. Observational
4.2.1.3. Expanded Access
4.3. North America Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. Autoimmune/Inflammation
4.3.1.1.1. Rheumatoid arthritis
4.3.1.1.2. Multiple Sclerosis
4.3.1.1.3. Osteoarthritis
4.3.1.1.4. Irritable Bowel Syndrome (IBS)
4.3.1.1.5. Others
4.3.1.2. Pain Management
4.3.1.2.1. Chronic Pain
4.3.1.2.2. Acute Pain
4.3.1.3. Oncology
4.3.1.3.1. Blood Cancer
4.3.1.3.2. Solid Tumors
4.3.1.3.3. Other
4.3.1.4. CNS Condition
4.3.1.4.1. Epilepsy
4.3.1.4.2. Parkinson's Disease (PD)
4.3.1.4.3. Huntington's Disease
4.3.1.4.4. Stroke
4.3.1.4.5. Traumatic Brain Injury (TBI)
4.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
4.3.1.4.7. Muscle Regeneration
4.3.1.4.8. Others
4.3.1.5. Diabetes
4.3.1.6. Obesity
4.3.1.7. Cardiovascular
4.3.1.8. Others
4.4. North America Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
4.4.1. Key Highlights
4.4.1.1. Protocol Designing
4.4.1.2. Site Identification
4.4.1.3. Patient Recruitment
4.4.1.4. Laboratory Services
4.4.1.5. Bioanalytical Testing Services
4.4.1.6. Clinical Trial Data Management Services
4.4.1.7. Others
4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
4.5.1. Key Highlights
4.5.1.1. U.S. Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
4.5.1.2. U.S. Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
4.5.1.3. U.S. Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
4.5.1.4. U.S. Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
4.5.1.5. Canada Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
4.5.1.6. Canada Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
4.5.1.7. Canada Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
4.5.1.8. Canada Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Clinical Trials Market Outlook, 2018 - 2030

5.1. Europe Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Phase I
5.1.1.2. Phase II
5.1.1.3. Phase III
5.1.1.4. Phase IV
5.2. Europe Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Interventional
5.2.1.2. Observational
5.2.1.3. Expanded Access
5.3. Europe Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. Autoimmune/Inflammation
5.3.1.1.1. Rheumatoid arthritis
5.3.1.1.2. Multiple Sclerosis
5.3.1.1.3. Osteoarthritis
5.3.1.1.4. Irritable Bowel Syndrome (IBS)
5.3.1.1.5. Others
5.3.1.2. Pain Management
5.3.1.2.1. Chronic Pain
5.3.1.2.2. Acute Pain
5.3.1.3. Oncology
5.3.1.3.1. Blood Cancer
5.3.1.3.2. Solid Tumors
5.3.1.3.3. Other
5.3.1.4. CNS Condition
5.3.1.4.1. Epilepsy
5.3.1.4.2. Parkinson's Disease (PD)
5.3.1.4.3. Huntington's Disease
5.3.1.4.4. Stroke
5.3.1.4.5. Traumatic Brain Injury (TBI)
5.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
5.3.1.4.7. Muscle Regeneration
5.3.1.4.8. Others
5.3.1.5. Diabetes
5.3.1.6. Obesity
5.3.1.7. Cardiovascular
5.3.1.8. Others
5.4. Europe Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
5.4.1. Key Highlights
5.4.1.1. Protocol Designing
5.4.1.2. Site Identification
5.4.1.3. Patient Recruitment
5.4.1.4. Laboratory Services
5.4.1.5. Bioanalytical Testing Services
5.4.1.6. Clinical Trial Data Management Services
5.4.1.7. Others
5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
5.5.1. Key Highlights
5.5.1.1. Germany Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.2. Germany Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.3. Germany Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.4. Germany Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.1.5. U.K. Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.6. U.K. Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.7. U.K. Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.8. U.K. Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.1.9. France Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.10. France Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.11. France Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.12. France Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.1.13. Italy Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.14. Italy Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.15. Italy Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.16. Italy Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.1.17. Russia Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.18. Russia Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.19. Russia Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.20. Russia Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.1.21. Rest of Europe Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.22. Rest of Europe Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.23. Rest of Europe Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.24. Rest of Europe Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Clinical Trials Market Outlook, 2018 - 2030

6.1. Asia Pacific Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
6.1.1. Key Highlights
6.1.1.1. Phase I
6.1.1.2. Phase II
6.1.1.3. Phase III
6.1.1.4. Phase IV
6.2. Asia Pacific Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Interventional
6.2.1.2. Observational
6.2.1.3. Expanded Access
6.3. Asia Pacific Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. Autoimmune/Inflammation
6.3.1.1.1. Rheumatoid arthritis
6.3.1.1.2. Multiple Sclerosis
6.3.1.1.3. Osteoarthritis
6.3.1.1.4. Irritable Bowel Syndrome (IBS)
6.3.1.1.5. Others
6.3.1.2. Pain Management
6.3.1.2.1. Chronic Pain
6.3.1.2.2. Acute Pain
6.3.1.3. Oncology
6.3.1.3.1. Blood Cancer
6.3.1.3.2. Solid Tumors
6.3.1.3.3. Other
6.3.1.4. CNS Condition
6.3.1.4.1. Epilepsy
6.3.1.4.2. Parkinson's Disease (PD)
6.3.1.4.3. Huntington's Disease
6.3.1.4.4. Stroke
6.3.1.4.5. Traumatic Brain Injury (TBI)
6.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
6.3.1.4.7. Muscle Regeneration
6.3.1.4.8. Others
6.3.1.5. Diabetes
6.3.1.6. Obesity
6.3.1.7. Cardiovascular
6.3.1.8. Others
6.4. Asia Pacific Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
6.4.1. Key Highlights
6.4.1.1. Protocol Designing
6.4.1.2. Site Identification
6.4.1.3. Patient Recruitment
6.4.1.4. Laboratory Services
6.4.1.5. Bioanalytical Testing Services
6.4.1.6. Clinical Trial Data Management Services
6.4.1.7. Others
6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
6.5.1. Key Highlights
6.5.1.1. China Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
6.5.1.2. China Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
6.5.1.3. China Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
6.5.1.4. China Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
6.5.1.5. Japan Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
6.5.1.6. Japan Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
6.5.1.7. Japan Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
6.5.1.8. Japan Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
6.5.1.9. India Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
6.5.1.10. India Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
6.5.1.11. India Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
6.5.1.12. India Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
6.5.1.13. Southeast Asia Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
6.5.1.14. Southeast Asia Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
6.5.1.15. Southeast Asia Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
6.5.1.16. Southeast Asia Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
6.5.1.17. Rest of Asia Pacific Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
6.5.1.18. Rest of Asia Pacific Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
6.5.1.19. Rest of Asia Pacific Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
6.5.1.20. Rest of Asia Pacific Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Clinical Trials Market Outlook, 2018 - 2030

7.1. Latin America Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Phase I
7.1.1.2. Phase II
7.1.1.3. Phase III
7.1.1.4. Phase IV
7.2. Latin America Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Interventional
7.2.1.2. Observational
7.2.1.3. Expanded Access
7.3. Latin America Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
7.3.1. Key Highlights
7.3.1.1. Autoimmune/Inflammation
7.3.1.1.1. Rheumatoid arthritis
7.3.1.1.2. Multiple Sclerosis
7.3.1.1.3. Osteoarthritis
7.3.1.1.4. Irritable Bowel Syndrome (IBS)
7.3.1.1.5. Others
7.3.1.2. Pain Management
7.3.1.2.1. Chronic Pain
7.3.1.2.2. Acute Pain
7.3.1.3. Oncology
7.3.1.3.1. Blood Cancer
7.3.1.3.2. Solid Tumors
7.3.1.3.3. Other
7.3.1.4. CNS Condition
7.3.1.4.1. Epilepsy
7.3.1.4.2. Parkinson's Disease (PD)
7.3.1.4.3. Huntington's Disease
7.3.1.4.4. Stroke
7.3.1.4.5. Traumatic Brain Injury (TBI)
7.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
7.3.1.4.7. Muscle Regeneration
7.3.1.4.8. Others
7.3.1.5. Diabetes
7.3.1.6. Obesity
7.3.1.7. Cardiovascular
7.3.1.8. Others
7.4. Latin America Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
7.4.1. Key Highlights
7.4.1.1. Protocol Designing
7.4.1.2. Site Identification
7.4.1.3. Patient Recruitment
7.4.1.4. Laboratory Services
7.4.1.5. Bioanalytical Testing Services
7.4.1.6. Clinical Trial Data Management Services
7.4.1.7. Others
7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
7.5.1. Key Highlights
7.5.1.1. Brazil Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
7.5.1.2. Brazil Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
7.5.1.3. Brazil Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
7.5.1.4. Brazil Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
7.5.1.5. Mexico Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
7.5.1.6. Mexico Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
7.5.1.7. Mexico Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
7.5.1.8. Mexico Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
7.5.1.9. Rest of Latin America Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
7.5.1.10. Rest of Latin America Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
7.5.1.11. Rest of Latin America Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
7.5.1.12. Rest of Latin America Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Clinical Trials Market Outlook, 2018 - 2030

8.1. Middle East & Africa Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Phase I
8.1.1.2. Phase II
8.1.1.3. Phase III
8.1.1.4. Phase IV
8.2. Middle East & Africa Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Interventional
8.2.1.2. Observational
8.2.1.3. Expanded Access
8.3. Middle East & Africa Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
8.3.1. Key Highlights
8.3.1.1. Autoimmune/Inflammation
8.3.1.1.1. Rheumatoid arthritis
8.3.1.1.2. Multiple Sclerosis
8.3.1.1.3. Osteoarthritis
8.3.1.1.4. Irritable Bowel Syndrome (IBS)
8.3.1.1.5. Others
8.3.1.2. Pain Management
8.3.1.2.1. Chronic Pain
8.3.1.2.2. Acute Pain
8.3.1.3. Oncology
8.3.1.3.1. Blood Cancer
8.3.1.3.2. Solid Tumors
8.3.1.3.3. Other
8.3.1.4. CNS Condition
8.3.1.4.1. Epilepsy
8.3.1.4.2. Parkinson's Disease (PD)
8.3.1.4.3. Huntington's Disease
8.3.1.4.4. Stroke
8.3.1.4.5. Traumatic Brain Injury (TBI)
8.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
8.3.1.4.7. Muscle Regeneration
8.3.1.4.8. Others
8.3.1.5. Diabetes
8.3.1.6. Obesity
8.3.1.7. Cardiovascular
8.3.1.8. Others
8.4. Middle East & Africa Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
8.4.1. Key Highlights
8.4.1.1. Protocol Designing
8.4.1.2. Site Identification
8.4.1.3. Patient Recruitment
8.4.1.4. Laboratory Services
8.4.1.5. Bioanalytical Testing Services
8.4.1.6. Clinical Trial Data Management Services
8.4.1.7. Others
8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
8.5.1. Key Highlights
8.5.1.1. GCC Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
8.5.1.2. GCC Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
8.5.1.3. GCC Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
8.5.1.4. GCC Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
8.5.1.5. South Africa Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
8.5.1.6. South Africa Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
8.5.1.7. South Africa Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
8.5.1.8. South Africa Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
8.5.1.9. Rest of Middle East & Africa Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
8.5.1.10. Rest of Middle East & Africa Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
8.5.1.11. Rest of Middle East & Africa Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
8.5.1.12. Rest of Middle East & Africa Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Key player vs Phase/Indication Heatmap
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Eli Lilly and Company
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Syneos Health
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Pharmaceutical Product Development (PPD)
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Novo Nordisk A/S
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Icon plc.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Charles River Laboratories
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Parexel International Corporation
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. WuXi Apptec
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Business Strategies and Development
9.4.9. Medpace Holdings, Inc.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. KCR Pharmaceuticals Pvt. Ltd.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Pharmaceutical Solutions Industry Ltd. (PSI).
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Pfizer
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Thermo Fisher Scientific Inc.
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development
9.4.14. Sanofi SA
9.4.14.1. Company Overview
9.4.14.2. Product Portfolio
9.4.14.3. Financial Overview
9.4.14.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Eli Lilly and Company
Syneos Health
Pharmaceutical Product Development (PPD)
Novo Nordisk A/S
Icon plc.
Charles River Laboratories
Parexel International Corporation
WuXi Apptec
Medpace Holdings, Inc.
KCR Pharmaceuticals Pvt. Ltd.
Pharmaceutical Solutions Industry Ltd. (PSI).
Pfizer
Thermo Fisher Scientific Inc.
Sanofi SA

Methodology

LOADING...

Leaders in Global clinical trials Space:

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Clinical Trial Kits Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global Cardiovascular Clinical Trials Market Analysis & Forecast to 2024-2034

Clinical Trial Management System Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global Clinical Trials Market (2023-2028) Impact of Covid-19, Ansoff Analysis

Global Immuno-oncology Clinical Trials Market by Design (Expanded Access Trials, Interventional Trials, Observational Trials), Phase (Phase I, Phase II, Phase III), Indication - Forecast 2024-2030